These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23064737)

  • 1. PET could predict response to neoadjuvant therapy and long-term survival of patients with esophageal cancer.
    Wang WP; Wang KN; Chen LQ
    World J Surg; 2013 Apr; 37(4):930-1. PubMed ID: 23064737
    [No Abstract]   [Full Text] [Related]  

  • 2. Accuracy of PET-CT in predicting survival in patients with esophageal cancer.
    Brown C; Howes B; Jamieson GG; Bartholomeusz D; Zingg U; Sullivan TR; Thompson SK
    World J Surg; 2012 May; 36(5):1089-1095. PubMed ID: 22374537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of ¹⁸F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy.
    Myslivecek M; Neoral C; Vrba R; Vomackova K; Cincibuch J; Formanek R; Koranda P; Zapletalova J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):171-9. PubMed ID: 22660205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Texture analysis of computed tomography data using morphologic and metabolic delineation of esophageal cancer-relation to tumor type and neoadjuvant therapy response.
    Zhang YH; Herlin G; Rouvelas I; Nilsson M; Lundell L; Brismar TB
    Dis Esophagus; 2019 Apr; 32(4):. PubMed ID: 30295752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy.
    Tan S; Kligerman S; Chen W; Lu M; Kim G; Feigenberg S; D'Souza WD; Suntharalingam M; Lu W
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1375-82. PubMed ID: 23219566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
    Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
    JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (18)F-FDG-PET/CT in assessing response to neoadjuvant chemoradiotherapy for potentially resectable locally advanced esophageal cancer.
    Metser U; Rashidi F; Moshonov H; Wong R; Knox J; Guindi M; Darling G
    Ann Nucl Med; 2014 May; 28(4):295-303. PubMed ID: 24474598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma.
    Gillies RS; Middleton MR; Han C; Marshall RE; Maynard ND; Bradley KM; Gleeson FV
    Br J Surg; 2012 Feb; 99(2):239-45. PubMed ID: 22329010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastases of esophageal carcinoma to skeletal muscle: single center experience.
    Cincibuch J; Mysliveček M; Melichar B; Neoral C; Metelková I; Zezulová M; Procházková-Študentová H; Flodr P; Zlevorová M; Aujeský R; Cwiertka K
    World J Gastroenterol; 2012 Sep; 18(35):4962-6. PubMed ID: 23002370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
    van Heijl M; Omloo JM; van Berge Henegouwen MI; Hoekstra OS; Boellaard R; Bossuyt PM; Busch OR; Tilanus HW; Hulshof MC; van der Gaast A; Nieuwenhuijzen GA; Bonenkamp HJ; Plukker JT; Cuesta MA; Ten Kate FJ; Pruim J; van Dekken H; Bergman JJ; Sloof GW; van Lanschot JJ
    Ann Surg; 2011 Jan; 253(1):56-63. PubMed ID: 21233607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advantages of positron emission tomography-computed tomography imaging in esophageal squamous cell carcinoma.
    Wang F; Shen LY; Ma SH; Li N; Yang Z; Chen KN
    Dis Esophagus; 2013; 26(8):832-7. PubMed ID: 22947128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The integration of 18-fluoro-deoxy-glucose positron emission tomography and endoscopic ultrasound in the treatment-planning process for esophageal carcinoma.
    Konski A; Doss M; Milestone B; Haluszka O; Hanlon A; Freedman G; Adler L
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1123-8. PubMed ID: 15752892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of lymphatic drainage and lymph node involvement in esophageal cancer.
    Howard JM; Johnston C
    Abdom Imaging; 2013 Apr; 38(2):233-43. PubMed ID: 22711183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole Body MRI in the Staging of Esophageal Cancer--A Prospective Comparison with Whole Body 18F-FDG PET-CT.
    Malik V; Harmon M; Johnston C; Fagan AJ; Claxton Z; Ravi N; O'Toole D; Muldoon C; Keogan M; Reynolds JV; Meaney JF
    Dig Surg; 2015; 32(5):397-408. PubMed ID: 26315570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of positron emission tomography in the (re-)staging of oesophageal cancer.
    Westerterp M; Van Westreenen HL; Sloof GW; Plukker JT; Van Lanschot JJ
    Scand J Gastroenterol Suppl; 2006; (243):116-22. PubMed ID: 16782630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic value of the metabolically active tumour volume].
    Paumier A; Marquis A; Trémolières P; Lacombe M; Capitain O; Septans AL; Peyraga G; Gustin P; Vénara A; Ménager É; Visvikis D; Couturier O; Rio E; Hatt M
    Cancer Radiother; 2016 Feb; 20(1):24-9. PubMed ID: 26762703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolated nasal tip metastasis from esophageal squamous cell carcinoma.
    Dong A; Zuo C; Wang Y; Zhai Z; Wen W
    Clin Nucl Med; 2015 Jan; 40(1):65-7. PubMed ID: 24566414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measuring tumor hypoxia with ¹⁸F-FETNIM PET in esophageal squamous cell carcinoma: a pilot clinical study.
    Yue J; Yang Y; Cabrera AR; Sun X; Zhao S; Xie P; Zheng J; Ma L; Fu Z; Yu J
    Dis Esophagus; 2012 Jan; 25(1):54-61. PubMed ID: 21595781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the diagnostic value of 3-deoxy-3-18F-fluorothymidine and 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of regional lymph node in thoracic esophageal squamous cell carcinoma: a pilot study.
    Han D; Yu J; Zhong X; Fu Z; Mu D; Zhang B; Xu G; Yang W; Zhao S
    Dis Esophagus; 2012 Jul; 25(5):416-26. PubMed ID: 21951837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.